Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 10 years after a previous dose
Journal of the Pediatric Infectious Diseases Society Feb 14, 2018
Halperin SA, et al. - An observer-blinded, randomized controlled trial was performed to assess the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 10 years (aged 18 to <65 years) after a previous dose. Findings revealed that in these adults, a second dose of Tdap vaccine was well tolerated and immunogenic. Findings thereby could facilitate consideration of providing Tdap booster doses to adults.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries